Novalung system receives US FDA clearance
With class II approval, the Novalung system is the first complete system approved for ECMO therapy and long-term use for a duration of more than six hours.
End of August 2019, Novalung GmbH became fully integrated within Xenios AG. “Novalung” will be retained as an established brand in the intensive care market and developed further with the support of Fresenius Medical Care as a key pillar in the area of multi-organ support.
End of 2016, Xenios AG became a part of Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure.
Novalung and Medos merge with the formation of a holding company, Xenios AG.
In 2011, Medos was acquired by Novalung with the aim of extending Medos’ blood pump expertise and blood pump technology for use with lung therapies. This acquisition enabled the company to expand its overall product spectrum to offer both heart and lung support on one single platform: the Xenios console.
Novalung was formed back in 2003. The aim of Novalung is to create new solutions for the treatment of acute and chronic lung failure. Novalung therapy can replace or supplement invasive mechanical ventilation and prevent ventilation-related lung damage.
Medos is experienced in cardiopulmonary solutions for more than 30 years. Highly skilled employees and high-quality manufacturing – for the benefit of cardiac surgeons, perfusionists and patients. Whether aortic valve replacement or bypass surgery, almost all cardiac surgery procedures can be performed effectively using Medos products.